Ajanta Pharma promoter Ravi Agrawal has disclosed pledge transactions involving 9,35,000 equity shares of the pharmaceutical company. The disclosure, made on March 30, 2026, covers both creation and release of pledges under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Transaction Details

The promoter created pledges for refinancing purposes while releasing existing pledges due to excess pledge requirements. The transactions were executed between March 25-27, 2026, involving multiple financial institutions.

Promoter Holdings Overview

Ravi Agrawal, acting as trustee of Ravi Agrawal Trust, holds 16,242,904 equity shares representing 13.00% of the company's total share capital. Following the pledge transactions, his total pledged shareholding stands at 6,063,920 shares, equivalent to 4.85% of the total share capital.

Regulatory Compliance

The disclosure was made in compliance with Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The formal communication was addressed to both BSE Limited and National Stock Exchange of India, where Ajanta Pharma shares are listed.

Promoter Group Structure

The disclosure also provides details of other promoter group entities and their shareholdings. The promoter group includes various family trusts and investment entities, with Yogesh Agrawal Trust and Rajesh Agrawal Trust each holding 14.47% of the company's shares, while Gabs Investments Pvt Ltd holds 10.08% of the total share capital.

The pledge transactions reflect ongoing financial management activities by the promoter group while maintaining substantial shareholding in the pharmaceutical company.

Ajanta Pharma promoter Aayush Agrawal has disclosed the creation and release of pledge on equity shares of the company on March 26, 2026. The disclosure was made under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, with formal notifications submitted to both BSE and NSE.

Latest Pledge Transaction Details

The recent pledge transactions by Aayush Agrawal involved creation of pledge on 10,42,500 shares and release of pledge on 8,50,000 shares. According to the disclosure, the creation of pledge was undertaken for new loan purposes, while the release was attributed to loan not taken.

Detailed Encumbrance Activities

The disclosure document shows multiple pledge activities involving different financial institutions as lenders. Aayush Agrawal Trust had existing encumbered holdings of 82,04,162 shares representing 6.57% of total share capital before the latest transactions.

Post-event, Aayush Agrawal Trust holds 83,96,662 encumbered shares representing 6.72% of the total share capital.

Comprehensive Promoter Holdings Structure

The detailed promoter holding disclosure reveals the comprehensive shareholding pattern of the Agrawal family and associated entities across multiple trusts and companies.

Regulatory Compliance

The disclosure fulfills the mandatory reporting requirements under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The formal communication was addressed to both stock exchanges where Ajanta Pharma shares are listed, ensuring complete regulatory compliance and transparency in promoter shareholding changes. Aayush Agrawal, acting as trustee of Aayush Agrawal Trust, submitted the required documentation with proper authorization and signatures.